David Sidransky

Tamir Biotechnology, Inc. engages in the discovering and developing of new class therapeutic drugs for the treatment of cancer and other pathological conditions. The firm's proprietary drug discovery program is also the basis for the development of recombinant designed RNases for chemical conjugation and fusion products with various targeting moieties, such as monoclonal antibodies, growth factors, and cytokines. The company was founded on August 24, 1981 and is headquartered in Short Hills, NJ.

Advaxis, Inc. is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins. The firm has four franchises in various stages of clinical and pre-clinical development, namely: HPV-associated cancers, prostate cancer, neoantigen therapy and hotspot mutation therapy. The company was founded on June 5, 1987 and is headquartered in Princeton, NJ.

Part of Champions Oncology, Inc., Biomerk, Inc. is a private company that owns and operates medical research laboratories. The company is based in Scottsdale, AZ. Biomerk was acquired by Champions Oncology, Inc. on May 18, 2007 for $1.16 million.

Celsus Therapeutics Plc is a drug development company, which focuses on developing novel, first-in-class, non-steroidal, synthetic anti-inflammatory drugs and multi-functional anti-inflammatory drugs. The company main clinical candidates are MRX-5, MRX-6, MRX-4, CFX-1 and OPX-1. Celsus Therapeutics was founded on October 7, 2004 and is headquartered in London, the United Kingdom.

ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ.

Immune Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases. Its lead product, Bertilimumab, is a human monoclonal antibody that binds eotaxin-1, a chemokine that attracts eosinophils to the site of inflammation. Bertilimumab has shown promising clinical activity in bullous pemphigoid and has been studied in other conditions including allergic rhinitis and ulcerative colitis, and may have application in other diseases, including atopic dermatitis, asthma, and other diseases. It is also developing NanoCyclo, a topical nano-encapsulated formulation of cyclosporine, for the treatment of atopic dermatitis (AD) and psoriasis. The company was founded by Daniel Gedeon Teper on March 9, 1993 and is headquartered in Englewood Cliffs, NJ.

AMAG Pharma USA, Inc. engages in the provision of pharmaceutical products to independent pharmacies, managed care organizations, hospitals, pharmacy benefit management companies, government entities, and physicians. The company was founded by Victor M. Hermelin in 1942 and is headquartered in Waltham, MA.

American Association for Cancer Research prints and publishes scientific journals including clinical cancer research, molecular cancer therapeutics, molecular cancer research, cancer epidemiology, and biomarkers and prevention. The company was founded on May 7, 1907 and is headquartered in Philadelphia, PA.

Zila, Inc., headquartered in Scottsdale, Arizona and founded in 1988, is a diagnostic company that offers prevention, detection and treatment of oral cancer and periodontal disease. Zila manufactures and markets ViziLite Plus with TBlue (“ViziLite Plus”), the company’s product for the detection of oral abnormalities that could lead to cancer. ViziLite Plus is a medical device for use in a popilation risking for oral cancer. Zila designs, manufactures and markets products sold directly to dental professionals for periodontal disease, including the Rotadent Professional Powered Brush, the Pro-Select Platinum ultrasonic scaler and oral pharmaceutical products for both in-office and home-care use

The Sidney Kimmel Comprehensive Cancer Center offers immune-based treatments for cancer. The company was founded by Sidney Kimmel in 1973 and is headquartered in Baltimore, MD.

The American Society of Clinical Oncology is a non-profit organization founded in 1964 with the overarching goals of improving cancer care and prevention. More than 27,000 oncology practitioners belong to ASCO, representing all oncology disciplines and subspecialties. Members include physicians and health-care professionals in all levels of the practice of oncology. American Society of Clinical Oncology is the world’s leading professional organization representing physicians who treat people with cancer. ASCO’s members set the standard for patient care worldwide and lead the way in carrying out clinical research aimed at improving the prevention, diagnosis, and treatment of cancer. ASCO's efforts are also directed toward advocating for policies that provide access to high-quality care for all patients with cancer and at supporting the increased funding for clinical and translational research.

Old Ayala, Inc. operates as a clinical-stage oncology company. It focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. It also involved in in precision oncology, targeted therapy, drug development, companion diagnostics, and biomarkers. The company was founded in November 2017 and is headquartered in Rehovot, Israel.

Exoprother Medical is an Israeli company that focuses on developing a cancer treatment inspired by evolution. The company is based in Yokne'am Illit, Israel. The company targets the p53 based tumor suppression mechanism that is mutated in over 60%% of cancers, including glioblastoma, colon, bladder, ovarian, and small cell lung cancers. The company uses exosomes, natural nano-particles produced by most living cells, to deliver healthy p53 and restore the body's natural tumor suppression function with minimal adverse side-effects. Exoprother Medical was founded by Lana Volokh and Alex Tendler, and Lana Volokh has been the CEO since incorporation.

Biond Biologics Ltd. engages in drug discovery and development. It offers cell-internalizing antibody platform that will enable antibody-targeting of intra-cellular immune factors. The company was founded by Ori Shilo and Tehila Ben-Moshe and is headquartered in Tel Aviv, Israel. The company was founded by Ori Shilo and Tehila Ben-Moshe and is headquartered in Tel Aviv, Israel.

Efranat Ltd. develops anti-cancer immunotherapy treatment. Its product is based on a natural plasma glycoprotein molecule that activates the innate immune system against cancer. The company was founded by Boaz Shoham, Nobuto Yamamoto and Avi Levin in 2009 and is headquartered in Rehovot, Israel.

Israel Biotech Fund (Israel Biotech) is a venture capital firm founded in 2015 by Yuval Cabilly, David Sidransky, and Gidon Zairi. The firm is headquartered in Rehovot, Israel.